A Study of SCTB35 in Patients with Systemic Lupus Erythematosus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-28

Study Completion Date

2028-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter Phase Ib/II clinical trial aimed at evaluating the safety, tolerability and efficacy of SCTB35 in patients with systemic lupus erythematosus (SLE).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

NCT06857214

Systemic Lupus Erythematosus

RECRUITING PHASE1

Study of CM355 in Patients With Systemic Lupus Erythematosus

NCT07104344

Systemic Lupus Erythematosus

NOT_YET_RECRUITING NA

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

NCT06826430

Autoimmune Thrombocytopenia

RECRUITING PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

NCT05155345

Systemic Lupus Erythematosus

COMPLETED PHASE1

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

NCT07177911

SLE - Systemic Lupus Erythematosus

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study contains the dose-escalation and dose-expansion parts. The escalation cohorts will be enrolled to explore the maximum tolerated dose and recommended phase II dose (RP2D). A Safety Review Committee (SRC) will review the accumulated safety data and other available data, and make a recommendation to each dose level of SCTB35 in the escalation cohorts. The expansion cohorts will be initiated after the RP2D is confirmed, and to further compare the preliminary efficacy and safety of SCTB35 at appropriate dose levels recommended by SRC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

System Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: SCTB35

SCTB35 will be administered every 21 days per treatment cycle.

Group Type EXPERIMENTAL

SCTB35 injection

Intervention Type BIOLOGICAL

SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SCTB35 injection

SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-75 years；
2. Diagnosed with SLE for ≥12 weeks prior to screening (2019-ACR/EULAR criteria);
3. SLEDAI-2K ≥ 8 at screening, or ≥6 if there is hypocomplementemia or elevated anti-dsDNA antibody levels;
4. Positive for ANA (1:80) or positive for anti-dsDNA and/or anti-Sm antibodies within the last 12 months or at screening;
5. Currently receiving ≥1 stable dose of standard treatment: oral corticosteroids, antimalarials, or conventional immunosuppressive drugs

1. Stable corticosteroid dose for ≥4 weeks prior to baseline;
2. Stable dose of antimalarial drugs for ≥4 weeks prior to baseline;
3. Stable dose of immunosuppressive agents for ≥4 weeks prior to baseline;
6. All male participants or females of reproductive potential must agree to use reliable contraception with their partner from signing the ICF through 6 months after the last dose of the study drug;
7. Understanding of the study procedures and voluntary signing of the informed consent form.

Exclusion Criteria

1. Severe active or unstable lupus-related neuropsychiatric disorders;
2. Other autoimmune diseases that may interfere with efficacy evaluation;
3. Catastrophic antiphospholipid syndrome;
4. Received treatments that may affect the drug's effect:
5. Received live vaccines or attenuated vaccines within 28 days prior to baseline or screening;
6. Clinically significant bleeding risk;
7. Abnormal laboratory results:

1. AST or ALT \>2.5 x ULN;
2. Total bilirubin \>1.5 x ULN;
3. ANC \<1.5x10⁹/L;
4. Platelets \<75x10⁹/L;
5. Hemoglobin \<100g/L;
8. eGFR \<30 mL/min/1.73 m²;
9. Positive serum HCG;
10. Received any investigational treatment within 30 days prior to baseline or within 5 half-lives of the investigational drug (whichever is longer);
11. Participants with recurrent, chronic, or other active infections as assessed by the investigator;
12. Severe or uncontrolled disease, which would prevent participation in the study;
13. Positive viral serology tests, including HIV, HCV, and HBV;
14. Tuberculosis screening: Known active tuberculosis or latent tuberculosis infection (LTBI);
15. Any type of active infection except nail bed fungal infections;
16. Severe infections;
17. History of progressive multifocal leukoencephalopathy (PML);
18. Diagnosed with type 1 or type 2 diabetes with poor control;
19. Uncontrolled hypertension (systolic \>140 mmHg or diastolic \>90 mmHg);
20. History of malignancy within 5 years prior to baseline;
21. Alcohol abuse or drug misuse within 12 months prior to screening;
22. Intolerance to the study drug or contraindications, including a history of severe allergic reactions to monoclonal antibodies or any component of SCTB35 injection;
23. Required hospitalization for major surgery within 4 weeks prior to screening or within 12 weeks post-study drug administration;
24. Participants with mental disorders or poor compliance;
25. Severe lupus nephritis;
26. History of solid organ or hematopoietic stem cell/bone marrow transplant, or expected to undergo transplant surgery during the study;
27. Pregnant or breastfeeding;
28. Any other condition that the investigator deems unsuitable for participation in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, , China

Site Status RECRUITING